Filtered By:
Specialty: Neurology
Condition: Allergy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 65 results found since Jan 2013.

Thrombotic Thrombocytopenic Purpura Without Schistocytes: Beware of Misdiagnosis
A 43-year-old woman was admitted for acute unusual headache, vertigo, and left upper limb weakness. She had been complaining of asthenia for the past few weeks. Her medical history included uterine cervix cancer treated with conisation and 2 pregnancies without serious complications. No allergy or recent drug introduction was noted. After ruling out current pregnancy, magnetic resonance imaging (MRI) was immediately performed and showed recent ischemic strokes in multiple territories. Doppler ultrasound imaging showed no carotid or vertebral arteries lesion. Electrocardiogram showed no ST elevation or atrial fibrillation, ...
Source: Neurology Clinical Practice - October 11, 2021 Category: Neurology Authors: Decker, P., Moulinet, T., Revuz, S., Perez, P., Jaussaud, R. Tags: Autoimmune diseases, Hematologic, All Cerebrovascular disease/Stroke Case Source Type: research

Safety of OnabotulinumtoxinA with Concomitant Antithrombotic Therapy in Patients with Muscle Spasticity: A Retrospective Pooled Analysis of Randomized Double-Blind Studies
ConclusionsNo apparent increased risk of bleeding complications was observed following administration of onabotulinumtoxinA to patients receiving antithrombotic therapy. Nonetheless, patient education and careful observation of the injection site in patients receiving antithrombotic therapy remains warranted.
Source: CNS Drugs - March 12, 2020 Category: Neurology Source Type: research

Neurological Involvement in Primary Systemic Vasculitis
Conclusion Neurological involvement is a common complication of PSV (Table 1), and neurologists play an important role in the identification and diagnosis of PSV patients with otherwise unexplained neurological symptoms as their chief complaint. This article summarizes the neurological manifestations of PSV and hopes to improve neuroscientists' understanding of this broad range of diseases. TABLE 1 Table 1. Common CNS and PNS involvements of primary systemic vasculitis. Author Contributions SZ conceived the article and wrote the manuscript. DY and GT reviewed and edited the manuscript. All authors ...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Combination of Dexmedetomidine and Ketamine for Magnetic Resonance Imaging Sedation
Conclusions: The efficacy of DEX–KET sedation was comparable to that of midazolam for MRI examination. DEX–KET was related to shorter scan time and lower occurrence of complications compared to midazolam. Introduction Neurocritically ill patients often require brain magnetic resonance imaging (MRI) in addition to conventional neurological evaluations. Brain MRI can reveal structural lesions with a high sensitivity due to its excellent spatial resolution and enhanced soft tissue contrast (1–3). To acquire MRI images, patients' cooperation is imperative. However, keeping patients with ...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

MCI subtypes are heterogeneous and preceded by different risk factors: A study on aMCI and naMCI incidence (P4.194)
Conclusions:Results suggested that aMCI and naMCI are inherently heterogeneous from the outset, illustrated by their different risk factors. Recognizing indicators of MCI prior to clinical presentation is critical in targeted interventions, early treatment, and prevention from rapid progression to dementia.Study Supported by:NIA grant: AG03949Sylvia and Leonard Marx FoundationDisclosure: Dr. Zammit has nothing to disclose. Dr. Lipton has received personal compensation from Allergan, American Headache Society, Autonomic Technologies, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Eli Lilly, eNeura Therapeutics,...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Zammit, A., Lipton, R., Katz, M., Derby, C., Hall, C. Tags: Behavioral and Cognitive Neurology: Neurodegenerative Disorders Source Type: research

Dextromethorphan/Quinidine Improved Symptoms of Pseudobulbar Affect Irrespective of Concomitant Antidepressant Use (P6.210)
Conclusions:In this analysis, DM/Q was associated with PBA symptom improvement regardless of concomitant antidepressant use at baseline.Study Supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Formella has received personal compensation for activities with Avanir Pharmaceuticals, Inc. as an employee. Dr. Alexander has nothing to disclose. Dr. Cutler has received personal compensation for activities with Acadia, Alkermes, Allergan, Arbor Pharmaceuticals, Avanir, Intra-Cellular Therapies, Ironshore, and Lundbeck. Dr. Cutler has received research support from Acadia, Akili, Interactive, Alkermes, Allergan, Avanir, Axso...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Formella, A. E., Alexander, D. N., Cutler, A. J., DAmico, S., Hammond, F. M., Sauve, W., Zorowitz, R. D., Siffert, J. Tags: Behavioral and Cognitive Neurology: Emotion/Behavior Source Type: research

Safety of OnabotulinumtoxinA Treatment With Concomitant Antithrombotic Therapy in Patients With Post-stroke Spasticity: A Pooled Analysis of Randomized, Double-Blind Studies (S56.008)
Conclusions:There is no apparent increased risk of bleeding complications in patients on antithrombotics following IM onabotA treatment; nonetheless, careful observation of the injection site and patient education of the potential for bleeding complications remain warranted.Study Supported by: Allergan plc, Dublin, IrelandDisclosure: Dr. Dimitrova has received personal compensation for activities with Allergan as an employee. Dr. Dimitrova holds stock and/or stock options in Allergan. Dr. James has received personal compensation for activities with Allergan and Chase Pharmaceuticals as an employee. Dr. Liu has received per...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Dimitrova, R., James, L., Liu, C., Orejudos, A., Yushmanova, I., Brin, M. Tags: Movement Disorders: Huntington ' s Disease and Drug-Induced Dyskinesias Source Type: research

Do patients with thalamic pain have a specific somatosensory phenotype? (P1.222)
Conclusions:The somatosensory phenotype of the CPSP patients was characterized by reduced sensation for vibration and light touch on the affected side. These patients showed mechanical hyperalgesia and more pronounced hypoesthesia, but no temperature perception abnormalities, compared to the control patients. Our results do not support the view that a specific dysfunction of the spinothalamic tract is involved in the pathogenesis of thalamic CPSP.Disclosure: Dr. Papadopoulou has nothing to disclose. Dr. Magon has nothing to disclose. Dr. Gaetano has received personal compensation for activities with Novartis Pharmaceutical...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Papadopoulou, A., Magon, S., Gaetano, L., Jaeger, Y., Kappos, L., Sprenger, T. Tags: Pain and Palliative Care Source Type: research

Effect of early use of AbobotulinumtoxinA (Dysport(R)) after stroke on spasticity progression: first results of a pilot study (P4.032)
Conclusions:Median time between first injection (administered in patients 2–12 weeks post-stroke, MAS ≥2) and appearance of reinjection criteria (signs of symptomatic spasticity) was statistically significantly longer with aboBoNT-A compared with placebo. Safety profile was consistent with the known profile of aboBoNT-A.Study Supported by:Study supported by IpsenDisclosure: Dr. Rosales has received personal compensation for activities with Ipsen and Pfizer as a scientific advisory board member and consultant. Dr. Goh has received personal compensation for activities with Sanofi Genzyme as a moderator. Dr. Kumthorn...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Rosales, R., Goh, K. J., Kumthornthip, W., Mazlan, M., Latif, L. A., De Los Santos, M. M., Chotiyarnwong, C., Tanvijit, P., Balcaitiene, J., Maisonobe, P., Kong, K.-H. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research

The Adult Spasticity International Registry (ASPIRE) Study: 1-Year Results (P4.034)
Conclusions:Findings demonstrate the real-world safety and effectiveness for onabotulinumtoxinA treatment in spasticity. Further analyses will explore clinical and burden outcomes and differences across etiology and presentation.Study Supported by: Allergan plcDisclosure: Dr. Francisco has received personal compensation for activities with Allergan, Ipsen, Mallinckrodt, and Merz. Dr. Francisco has received personal compensation in an editorial capacity for Journal of Rehabilitation Medicine. Dr. Francisco has received research support from Allergan, Ipsen, Mallinckrodt, Medtronic, Merz, Microtransponder, and Nexstim. Dr. B...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Francisco, G. E., Bandari, D. S., Bavikatte, G., Jost, W. H., Adams, A. M., Largent, J., Esquenazi, A. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research

Duration of Treatment Effect of IncobotulinumtoxinA in Upper Limb Spasticity (P4.036)
Conclusions:These results demonstrate variability in the duration of treatment effect, which supports the use of flexible and individualized dosing intervals for the treatment of ULPSS. The duration of treatment effect was ≥14 weeks after most treatments; however, a considerable proportion of patients experienced effects lasting up to 20 weeks.Study Supported by: Merz Pharmacueticals GmbHDisclosure: Dr. Rubin has received personal compensation for activities with Allergan and Merz as a speaker and advisory board member. Dr. Kanovsky has received research support from Merz. Dr. Elovic has received personal compensation f...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Rubin, B., Kanovsky, P., Elovic, E., Munin, M., Althaus, M., Hanschmann, A., Pulte, I., Marciniak, C. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research

Duration of effect of abobotulinumtoxina (dysport(r)) in adult patients with upper limb spasticity (uls) post-stroke or traumatic brain injury (p4.038)
Conclusions:These data show that 24% to 37% of subjects did not require re-injection before Week 16 across multiple cycles. This longer duration to re-treatment may reduce the burden associated with frequency of injections for patients and their caregivers/families. This also highlights the needs for a tailored approach in the treatment of patients with ULS.Study Supported by:Study supported by IpsenDisclosure: Dr. Gracies has received research support from Ipsen. Dr. Brashear has received personal compensation for activities with Ipsen, Worldmeds and Revance as a consultant. Dr. Marciniak has received personal compensatio...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Gracies, J.-M., Brashear, A., Marciniak, C., Jech, R., Banach, M., Marque, P., Grandoulier, A.-S., Vilain, C., Picaut, P. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research

A novel CABC1/ADCK3 mutation in Adult-onset cerebellar ataxia (P6.021)
Conclusions:This is the first report of a duplication mutation on ADCK3/CABC1 in a patient with adult-onset progressive ataxia, chronic motor tics and familial seizures. Further studies are needed to elucidate whether the gain of function or a duplication-induced loss of function play a role in the pathophysiology of this condition.Disclosure: Dr. Malgireddy has nothing to disclose. Dr. Thompson has nothing to disclose. Dr. Torres-Russotto has received pesonal compensation for activities with Abbvie, Allergan, the American Parkinson Disease Foundation (APDA), Lundbeck, Teva, Huntington Disease Society of America (HDSA), Pa...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Malgireddy, K., Thompson, R., Torres-Russotto, D. Tags: Movement Disorders: Tics, Tremor & amp;amp; Ataxia II Source Type: research

Bad News or Life Altering Diagnoses? Neurology Residents Attitudes towards Disclosing Diagnoses (P1.048)
Conclusions:How we perceive a diagnosis may be related to the language we use such as a diagnosis being called "bad news" versus "life altering."Study Supported by: Supported by a grant from the University Hospital Foundation, Edmonton, Alberta, CanadaDisclosure: Dr. Miyasaki has received research support from Allergan. . Dr. Bell has nothing to disclose. Dr. Hodgson has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Miyasaki, J., Bell, C., Hodgson, C. Tags: Graduate Medical Education Research Source Type: research

Safety and Efficacy of High-Dose OnabotulinumtoxinA for Post-Stroke Upper Limb Spasticity: Results of a Double-Blind, Placebo-Controlled Trial (P3.027)
Conclusions:Preliminary results from this trial investigating the safety and efficacy of higher-dose onabotA for elbow and shoulder spasticity indicate a dose-related benefit. At the higher total dose of 500U onabotA, no new safety signals were observed; AEs did not appear to be dose-related.Study Supported by: Allergan plcDisclosure: Dr. Patel has received personal compensation for activities with Allergan, Merz, and Ipsen as a speaker and member of scientific advisory boards. Dr. Patel has received research support from Allergan, Merz, Ipsen, and Revance. Dr. Geis has received personal compensation for activities with Al...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Patel, A., Geis, C., Alter, K., Pan, G., Thorpe, A., James, L., Dimitrova, R. Tags: Movement Disorders: Dystonia and Neurotoxin Therapies Source Type: research